TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2903110
Drug: Salazopyrin (sulfasalazine)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salazopyrin (sulfasalazine) 3 g t.i.d.
Study: 28745686
Drug: LPD (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPD (0.6 g of protein per kg of body weight/day) with keto/amino acid ketosteril (1 tablet per 5 kg of body weight/day)
Study: 28745686
Drug: LPD (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPD (0.6 g of protein per kg of body weight/day) with keto/amino acid ketoaminol (1 tablet per 5 kg of body weight/day)
Study: 24120216
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) 600 mg once-daily
Study: 24120216
Drug: Nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (NVP) 400 mg once-daily
Study: 17154666
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with beta-lactam plus macrolide
Study: 17154666
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with respiratory fluoroquinolone
Study: 17154666
Drug: Beta-lactam alone
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam alone at adequate dosage
Study: 11012656
Drug: Saline (dummy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (dummy injection)
Study: 3917884
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate infusion
Study: 3917884
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution (saline) infusion
Study: 28865067
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment in sleep unit (SU) setting
Study: 28865067
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment in primary care (PC) setting
Study: 20102888
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy (low-dose bisoprolol regimen started ≥30 days before surgery)
Study: 20102888
Drug: No beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blocker therapy (control group)
Study: 17469694
Drug: Lithium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium plus fluoxetine
Study: 16036038
Drug: Fibrinolysis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolysis treatment
Study: 12073958
Drug: Self-monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring of blood glucose (SMBG), measured 4 times daily using a reflectance meter with memory
Study: 9796636
Drug: PXM 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXM 10 mg every other day (q.o.d.)
Study: 9796636
Drug: DFMO 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO 0.5 g/m2
Study: 9796636
Drug: PXM 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXM 10 mg q.o.d.
Study: 9796636
Drug: DFMO/PXM combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO/PXM combination
Study: 24477618
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of α‐lipoic acid (ALA) 600 mg and superoxide dismutase (SOD) 140 IU daily with physiotherapy
Study: 15992517
Drug: Esterified plant
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified plant stanols (2 to 3 g/day) incorporated in margarines or spreads
Study: 10102975
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg ranitidine
Study: 7568481
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg/kg plus ketamine 0.4 to 0.5 mg/kg
Study: 2174783
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) s.c. every 12 h, initial dose about 100 U/kg bodyweight
Study: 31626649
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (0.25 mg)
Study: 15709843
Drug: Teacher-administered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teacher-administered cognitive-behavioral intervention
Study: 10784384
Drug: Antioxidant supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplement (beta-carotene, lycopene, lutein, canthaxanthin, alpha-tocopherol) without dietary fiber
Study: 10784384
Drug: Antioxidant supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplement with pectin
Study: 10784384
Drug: Antioxidant supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplement with guar
Study: 10784384
Drug: Antioxidant supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplement with cellulose
Study: 6989687
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 100 mg slow-release tablets (morning or evening dose)
Study: 6989687
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg enteric-coated tablets b.i.d.
Study: 30908338
Drug: Test lens
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test lens with 0.019 mg ketotifen
Study: 30908338
Drug: Control lens
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control lens with no added drug
Study: 23570863
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate 800 mg QD for 15 days with OC
Study: 23570863
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate 1200 mg QD for 15 days with OC
Study: 23570863
Drug: OC alone
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC alone (30 μg ethinylestradiol and 150 μg levonorgestrel)
Study: 19906341
Drug: Desvenlafaxine (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (fixed doses: 50, 100, 200, or 400 mg/d; flexible doses: 100-400 mg/d)
Study: 17881750
Drug: Repeat doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat doses of antenatal corticosteroids (11.4 mg of betamethasone, intramuscular injection, repeated weekly if at risk for preterm delivery)
Study: 17881750
Drug: Repeat doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat doses of antenatal corticosteroids
Study: 12548591
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg intravenously)
Study: 11780252
Drug: Polyphenol tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol tablet, 3 times a day for 2 weeks, followed by 6 weeks of continued use for group B.
Study: 11780252
Drug: Polyphenol tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol tablet, after stopping use for 3 weeks.
Study: 1293241
Drug: SMS 201‐995
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS 201‐995 therapy (100 micrograms t.d.s. for 5 days)
Study: 6539322
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 25% albumin solution
Study: 6539322
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of 25% albumin solution
Study: 6539322
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 0.9% saline
Study: 6539322
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of 0.9% saline
Study: 31014399
Drug: High-dose IFNα
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFNα
Study: 25496405
Drug: Rituximab infusion
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab infusion at a weekly dose of 375 mg/m2 for 4 weeks plus oral daily prednisolone
Study: 21114550
Drug: Cobalt (Co)
Normalized name: Cobalt
DrugBank: Cobalt (DB14574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobalt (Co) 59mg intramuscular injection diluted in 5ml 0.9% saline solution twice a day
Study: 21114550
Drug: Control (5ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5ml 0.9% saline solution intramuscular injection twice a day)
Study: 18095751
Drug: Mucoadhesive patch
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mucoadhesive patch containing citrus oil and magnesium salts
Study: 18095751
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution containing benzocaine and compound benzoin tincture
Study: 15014007
Drug: ACA125 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACA125 vaccine
Study: 11500526
Drug: Leptin 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin 0.3 mg/kilogram subcutaneously for 6 days
Study: 8307916
Drug: endoscopic sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: endoscopic sclerotherapy along with ranitidine 300 mg daily
Study: 3500688
Drug: 5-hydroxytryptophan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxytryptophan (200 mg, orally)
Study: 30062794
Drug: Psyllium 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium 7 g t.d.s.
Study: 27656054
Drug: Conventional apical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional apical preparation (CAP)
Study: 22747899
Drug: FENO-driven therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FENO-driven therapy
Study: 8666450
Drug: Transmandibular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmandibular implant group
Study: 8666450
Drug: Endosseous implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endosseous implant group
Study: 1730190
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g i.v. t.i.d.
Study: 1730190
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g every 24 hr
Study: 4053132
Drug: Thiazide diuretic-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic-based antihypertensive therapy regimens
Study: 31626127
Drug: Rational-Emotive Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational-Emotive Behavior Therapy (REBT) for 10 weeks with 8 weeks follow-up
Study: 23934088
Drug: 5% potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% potassium nitrate as a desensitizing agent 30 min before bleaching with 28% hydrogen peroxide activated by LED
Study: 8639011
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no testosterone treatment)
Study: 16164657
Drug: Ferumoxytol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol (4 doses of 255 mg iron in 2 weeks or 2 doses of 510 mg iron in 1 to 2 weeks)
Study: 11401916
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g of DFMO
Study: 11401916
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g of DFMO
Study: 9462972
Drug: Triflusal treatment
Normalized name: triflusal
DrugBank: Triflusal (DB08814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal treatment
Study: 3896411
Drug: Naltrexone 200
Normalized name: NALTREXONE 200 mg / TRIAMCINOLONE 6.5 mg SUBCUTANEOUS IMPLANT [Naltrexone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 200 mg
Study: 3896411
Drug: Naltrexone 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 300 mg
Study: 3896411
Drug: Acetaminophen placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen placebo
Study: 3896411
Drug: Naltrexone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (all doses combined)
Study: 29772111
Drug: Human chorionic
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human chorionic gonadotropin (hCG) 5000 IU injections twice weekly
Study: 29772111
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Clomiphene citrate and hCG (CC + hCG)
Study: 27578477
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg tiotropium
Study: 27578477
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg glycopyrronium
Study: 22817672
Drug: Warmed intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed intraoperative irrigation solutions
Study: 22817672
Drug: Both preoperative
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preoperative warming and warmed intraoperative irrigation solutions
Study: 20405054
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg/day) alone for 6 weeks
Study: 20405054
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg/day) + Ivermectin (150 microg/kg) at +4 months
Study: 15964448
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg per day for 8 weeks)
Study: 12574183
Drug: Troglitazone (Tgz)
DrugBank: Troglitazone (DB00197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Troglitazone (Tgz) 600 mg/d for 3 months
Study: 3924065
Drug: Acipimox (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (750 mg/day)
Study: 28117627
Drug: Manual-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual-based treatment for school refusal
Study: 24347426
Drug: Raloxifene 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 120 mg/day for 1 month
Study: 24347426
Drug: Estrogen (E₂)
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (E₂) 4 mg/day for 1 month
Study: 24347426
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment alone (0.5 mg/day) for 1 month
Study: 24347426
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment with raloxifene (60 mg/day) for 1 month
Study: 24347426
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment with estrogen (2 mg/day) for 1 month
Study: 24347426
Drug: Raloxifene administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene administration
Study: 21098449
Drug: varespladib 500
Normalized name: Varespladib
DrugBank: Varespladib (DB11909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: varespladib 500 mg PO BID
Study: 11025624
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyproheptadine and propranolol
Study: 1335645
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of live attenuated hepatitis A vaccine at doses of 10(4), 10(5), 10(6), and 10(7) TCID50
Study: 1335645
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of live attenuated hepatitis A vaccine at doses of 10(6) and 10(7) TCID50
Study: 6363896
Drug: Human (semisynthetic)
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human (semisynthetic) insulin
Study: 27544023
Drug: Ahmed‐FP7 implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ahmed‐FP7 implant
Study: 22221551
Drug: Sclerotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerotherapy with 75% glucose solution
Study: 20929599
Drug: Extrafine BDP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafine BDP, 100 μg, b.i.d.
Study: 20929599
Drug: Nonextrafine BDP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonextrafine BDP, 250 μg, b.i.d.
Study: 19100092
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (AADs) for 3 months
Study: 10774084
Drug: Baseline studies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline studies prior to randomisation to antimalarial prophylactic regimens
Study: 6349608
Drug: Methazolamide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methazolamide (150 mg/d)
Study: 2803090
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg/d)
Study: 6349608
Drug: Methazolamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methazolamide (100 mg/d) at low altitude
Study: 28247654
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for acute serous and purulent pyelonephritis
Study: 25579161
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (G group)
Study: 16183220
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (10mg per day)
Study: 10989855
Drug: Intramuscular laryngeal
Normalized name: LARYNGEAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular laryngeal electromyography
Study: 1797191
Drug: 773U82.HCl at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 773U82.HCl at doses ranging from 15 mg/m2 to 980 mg/m2
Study: 1797191
Drug: 773U82.HCl at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 773U82.HCl at 980 mg/m2
Study: 1797191
Drug: 773U82.HCl at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 773U82.HCl at 720 mg/m2
Study: 1797191
Drug: 773U82.HCl infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 773U82.HCl infusion duration increase
Study: 6679239
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cost education and cost audits
Study: 30669797
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 ml normal saline)
Study: 26012474
Drug: Nicorandil administration
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil administration after primary PCI
Study: 23719148
Drug: Quality Improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality Improvement Tool - Pocket reminder card with preventive medication guidelines
Study: 23719148
Drug: Quality Improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality Improvement Tool - Monthly team feedback reports
Study: 8626882
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg COER-verapamil at 8:00 AM on an empty stomach, subjects remaining ambulatory
Study: 8626882
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg COER-verapamil at 8:00 AM on an empty stomach, subjects remaining supine for 8 hours
Study: 8626882
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg COER-verapamil at 10:00 PM with a standardized meal, subjects remaining supine for 8 hours
Study: 8626882
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg COER-verapamil at 10:00 PM on an empty stomach, subjects remaining supine for 8 hours
Study: 8626882
Drug: Time of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time of dosing
Study: 2906457
Drug: roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine acetate 75 mg
Study: 2905253
Drug: roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine acetate 150 mg
Study: 2906457
Drug: roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine acetate 300 mg
Study: 2906457
Drug: roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine acetate 600 mg
Study: 352976
Drug: Chlorpromazine treatment
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine treatment
Study: 23376852
Drug: No adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjunctive treatment (control group II)
Study: 20150572
Drug: Bevacizumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (both doses)
Study: 19968384
Drug: CT +
Normalized name: Aveeno Protect + Hydrate SPF70 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT + pharmacotherapy
Study: 16364575
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of trimegestone (TMG)
Study: 15365734
Drug: roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 300 mg/OD for 6 weeks
Study: 20642906
Drug: Bezafibrate 400
Normalized name: bezafibrate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate 400 mg
Study: 9365041
Drug: Immunohistochemistry using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemistry using QB monoclonal antibody
Study: 1562863
Drug: 10, 20
Normalized name: Co-Q10, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10, 20 or 30 mg/day of oral fluphenazine hydrochloride
Study: 26768569
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment alternatives for Ebola virus, including repurposed drugs; specific dosages and durations not mentioned.